Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Neutral on Humacyte, Raises Price Target to $4

Author: Benzinga Newsdesk | March 08, 2024 09:32am
Piper Sandler analyst Matt OBrien maintains Humacyte (NASDAQ:HUMA) with a Neutral and raises the price target from $3 to $4.

Posted In: HUMA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist